Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia

International Clinical Psychopharmacology

Volumn 25, Issue 5, 2010, Pages 264-269

  Souza, Renan P ^a,b,c   Remington, Gary ^a,b   Meltzer, Herbert Y ^d   Lieberman, Jeffrey A ^e   Kennedy, James L ^a,b   Wong, Albert H C ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VANDERBILT UNIVERSITY   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Abnormal Involuntary Movement Scale; extrapyramidal symptoms; movement disorders; pharmacogenomics; rolipram

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; YOUNG ADULT;

EID: 77955470316     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833a5ff9     Document Type: Article

References (41)

1. Aberg K, Adkins DE, Bukszar J,Webb BT, Caroff SN, Miller del D, et al. (2010). Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67:279-282
2. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009). Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 206:491-499
3. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
4. Bender R, Lange S (1999). Multiple test procedures other than Bonferroni's deserve wider use. BMJ 318:600-601
5. Bradshaw NJ, Ogawa F, Antolin-Fontes B, Chubb JE, Carlyle BC, Christie S, et al. (2008). DISC1, PDE4B, and NDE1 at the centrosome and synapse. Biochem Biophys Res Commun 377:1091-1096
6. Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK (2008). The DISC locus in psychiatric illness. Mol Psychiatry 13:36-64
7. Dlaboga D, Hajjhussein H, O'Donnell JM (2008). Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B,-4B, and-10A expression in rat striatum. Neuropharmacology 54:745-754
8. Durrant C, Zondervan KT, Cardon LR, Hunt S, Deloukas P, Morris AP (2004). Linkage disequilibrium mapping via cladistic analysis of single-nucleotide polymorphism haplotypes. Am J Hum Genet 75:35-43
9. Ezrin-Waters C, Seeman MV, Seeman P (1981). Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables. J Clin Psychiatry 42:16-22
10. Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, et al. (2008). PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 101:36-49
11. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H (1964). Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 40:10-27
12. Gauderman WJ (2002). Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 21:35-50
13. Hebb AL, Robertson HA, Denovan-Wright EM (2004). Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967-981
14. Houslay MD, Schafer P, Zhang KY (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519
15. Kahler AK, Otnaess MK, Wirgenes KV, Hansen T, Jonsson EG, Agartz I, et al. (2010). Association study of PDE4B gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples. Am J Med Genet B Neuropsychiatr Genet 153B:86-96
16. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP (2007). Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144:239-246
17. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, et al. (2005). Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8:411-425
18. Noble WS (2009). How does multiple testing correction work? Nat Biotechnol 27:1135-1137
19. Numata S, Ueno S, Iga J, Song H, Nakataki M, Tayoshi S, et al. (2008). Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population. J Psychiatr Res 43:7-12
20. Parkes JD, Thompson C, Brennan L, Gajraj N, Howcroft B, Ruiz J (1984). Rolipram in Parkinson's disease. Adv Neurol 40:563-565
21. Pickard BS, Thomson PA, Christoforou A, Evans KL, Morris SW, Porteous DJ, et al. (2007). The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr Genet 17:129-133
22. Porsolt RD, Moser PC, Castagne V (2010). Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther. doi: 10.1124/jpet.110.166710
23. Rastogi A, Zai C, Likhodi O, Kennedy JL,Wong AH (2009). Genetic association and post-mortem brain mRNA analysis of DISC1 and related genes in schizophrenia. Schizophr Res 114:39-49
24. Remington G (2007). Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 20:131-137
25. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M (1995a). Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 282:71-76
26. Sasaki H, Hashimoto K, Maeda Y, Inada T, Kitao Y, Fukui S, et al. (1995b). Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 56:PL443-PL447
27. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487
28. Seeman P, Lee T (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219
29. Siuciak JA, Chapin DS, McCarthy SA, Martin AN (2007). Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 192:415-424
30. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2010a). Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20:274-276
31. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2010b). Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol. doi: 10.1017/S1461145710000167
32. Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Macneil LT, Culotti JG, et al. (2010c). Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res. doi: 10.1016/j. jpsychires.2010.01.002
33. Souza RP, de Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, Wong AH (2010d). Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology (Berl). doi: 10.1007/s00213-010-1829-4
34. Tenback DE, van Harten PN, Slooff CJ, van Os J (2006). Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10 000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 163:1438-1440
35. Thelma B, Srivastava V, Tiwari AK (2008). Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 9:1285-1306
36. Van Os J,Walsh E, Van Horn E, Tattan T, Bale R, Thompson SG (1999). Tardive dyskinesia in psychosis: are women really more at risk? UK700 Group. Acta Psychiatr Scand 99:288-293
37. Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983). Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530-532
38. Weinhold P, Wegner JT, Kane JM (1981). Familial occurrence of tardive dyskinesia. J Clin Psychiatry 42:165-166
39. Woods SW, Morgenstern H, Saksa JR,Walsh BC, Sullivan MC, Money R, et al. (2010). Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. doi: 10.4088/JCP.07m03890yel
40. Yassa R, Ananth J (1981). Familial tardive dyskinesia. Am J Psychiatry 138:1618-1619
41. Zhang XY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, et al. (2009). Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berl) 205:647-654